Navigation Links
Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients
Date:11/29/2007

r cell-destroying, T- cells against tumor cells, and may represent a new therapeutic approach to cancer therapy. BiTE molecules are part of a novel class of antibody derivatives with the potential to selectively direct and activate an individual's cytotoxic T-cells, the body's most potent killer cells, to act against cancer cells. BiTE antibodies have been shown to induce an immunological synapse between a T-cell and a tumor cell in the same manner as observed during physiological T-cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T-cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as "apoptosis," or programmed cell death. In the presence of BiTE antibodies, T-cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at low concentrations and at low ratios of T-cells to target tumor cells. Through the process of killing cancer cells, T-cells proliferate, which leads to an increased number of T-cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE product development platform. In addition to current studies of MT103, three other BiTE antibodies, targeting EpCAM (CD326), CEA and MCSP, are in pre-clinical development.

BiTE is a registered trademark of Micromet.

About MT103

MT103, which is being co-developed with MedImmune as MEDI-538, is a BiTE antibody being developed with the intent to treat certain types of B-cell lymphomas. In February 2006, the U.S. Food and Drug Administration approved an orphan drug designation for MT103 for certain indolent B-cell lymphoma, excluding chronic lymphocytic leukemia and NHL with central nervous system involvement. MT103 also received orphan drug designation from the European Agency for the Evaluation of Medicinal Products for MCL and chronic lymphocytic leukemia
'/>"/>

SOURCE Micromet, Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
7. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 The Governor of Yucatán, ... at a press conference; this event is organized ... Ministry of Economy through the National Microenterprise Financing Program ... 2nd to the 5th at the Convention Center Yucatan ... is a great responsibility for Yucatan to host the ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for ... new world’s record by walking 5,000 miles in a single ... amazed by the thousands of individual stories of TrekDesk treadmill ... stand out more than the others. , Kirklyn has launched ... which tallies a range of 54,823 steps (presumably on an ...
(Date:8/28/2014)... Bank lending to the private sector in the ... in real terms, and continuing to fall behind the rest ... the international accountancy network. , UHY warns that the figures ... credit crunch lingers on. , UHY says in the US, ... been wiped out by inflation. Over the four years since ...
(Date:8/28/2014)... sleep not only puts teens at risk for poor grades, ... warn. The study authors analyzed data collected from more ... Nearly one-fifth of them got less than six hours of ... group was 20 percent more likely to be obese at ... of sleep per night at age 16, the investigators found. ...
(Date:8/28/2014)... the earliest birds take wing? Did they fall from trees ... did they run along the ground and pump their "arms" ... years in the past, but a new University of California, ... have an innate ability to maneuver in midair, a talent ... than fall from a perch. , The study looked at ...
Breaking Medicine News(10 mins):Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3
... ... set…GO! Summer kicks off each year with the City of Laguna ... year, the event is expected to bring out more than 6,000 runners, ... Day – Monday May 31. Registration is available online at www.lagunahillshalfmarathon.com ...
... , ... its place as one of the world,s leading medical hubs as it performs an ... and debilitating condition. , ... Singapore (PRWEB), May 6, 2010 -- Singapore,s oldest and largest tertiary acute hospital ...
... imaging (MRI) should be the imaging modality of choice for ... spread beyond the breast) as it is highly accurate and ... (shows no symptoms), according to a study to be presented ... Whole body MRI is a noninvasive medical test that ...
... Results from the SPIRIT IV clinical trial, which were ... scientific symposium, were published today in the New ... trial, a large-scale multi-center study of nearly 4,000 patients ... safety and efficacy in the treatment of de novo ...
... ... questions in the "By the Way, Doctor" feature. The newsletter,s May 2010 issue answers 13 ... Boston ... Letter offers answers to readers, serious, whimsical, and just plain curious questions ranging from ...
... discovered that the ovarian hormone progesterone plays a pivotal ... has important implications for breast cancer risk. ... (10.1038/nature09091; http://dx.doi.org/ ), are significant because reproductive history ... says principal investigator Rama Khokha, a molecular biologist at ...
Cached Medicine News:Health News:City of Laguna Hills Announces Memorial Day Half Marathon and 5K 2Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 2Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 3Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 4Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 5Health News:Whole body MRI is highly accurate in the early detection of breast cancer metastases 2Health News:Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent 2Health News:Harvard Health Letter Features Q&As from Harvard Doctors 2Health News:PMH cancer researchers link ovarian hormone to breast stem cells growth 2
(Date:8/28/2014)... The new report by ... applications, techniques, end users and Geography) Global Size, ... - 2020," indicates that the global DNA diagnostics ... a CAGR of 9.8% from 2014 to 2020. ... effectiveness over alternative diagnostic techniques are factors which ...
(Date:8/28/2014)... , Aug. 28, 2014   Venaxis, Inc. ... focused on obtaining FDA clearance for and commercializing its ... test for aiding in identifying children, adolescent, and young ... low risk for appendicitis, today announced it will present ... 16 th Annual Global Investment Conference being held ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... to 2020 - Broadened Diagnostic Criteria ... Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 - ...
Breaking Medicine Technology:DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8
... Encouraging 12-Month Outcomes from, Single- Center Study Involving ... 14 OrbusNeich today announced that an,interim analysis ... show good safety and efficacy in the real-world ... Presented by Professor Robbert de Winter, M.D., Ph.D., ...
... study Study needed ... Oct. 13 Advanced Circulatory Systems, Inc.,( http://www.advancedcirculatory.com ) ... in funding from the National Institutes of,Health (NIH) to ... on,those who experience cardiac arrest outside a hospital. Whatcom ...
Cached Medicine Technology:Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Medicine Products: